US 8,945,832 B2 · Treatment prediction involving HMGCR

Abstract

The present invention provides a method for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment, comprising the steps of: providing a sample earlier obtained from said subject; evaluating the amount of HMGCR protein or HMGCR mRNA present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the sample value obtained in step b) with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment. Further, a corresponding method of treatment is provided as well as further methods uses and means which may be employed in connection with breast cancer treatment or treatment prediction.

Claims16

Dependent claims

Method of treatment of a mammalian subject in need thereof, wherein said subject has a breast cancer, comprising the steps of:

a) providing a sample earlier obtained from said subject;
b) evaluating the amount of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) protein or HMGCR mRNA present in at least part of said sample, and determining a sample value corresponding to said amount;
c) comparing the sample value obtained in step b) with a reference value;
and, if said sample value is higher than said reference value,
d) treating said subject with an endocrine treatment regimen,
wherein said endocrine treatment is a selective estrogen receptor modulator (SERM) treatment.

3 more elements

Dependencies are inferred from the claim text.

Treatment prediction involving HMGCR

Life of this patent

Treatment prediction involving HMGCR

Life of this patent

Abstract

Claims16